Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: Perioperative pharmacologic bone-health optimization is increasingly recommended before lumbar fusion, but the supporting evidence may not apply to short-segment degenerative fusion. This scoping review mapped how well treatment recommendations are supported in that population. RECENT FINDINGS: Of 1,842 records screened, 145 underwent full-text review and 54 met inclusion criteria. Most high-level evidence pooled degenerative disease with adult spinal deformity and osteoporotic vertebral fracture without construct-specific analysis. In short-segment degenerative fusion, small teriparatide studies reported lower screw loosening and higher or earlier union, whereas a 1,040-patient registry found no reduction in operative nonunion with preoperative bisphosphonates. High-quality short-segment data for romosozumab and abaloparatide were absent, and timing and duration were inconsistent. Recommendations are supported by biologic rationale but limited by population mismatch. Teriparatide has the strongest degenerative-specific signal; evidence for bisphosphonates and newer agents is insufficient. Future trials should isolate 1- to 2-level degenerative fusion and prioritize cage subsidence, screw loosening, fusion, and reoperation.
No takes yet. Share an insight, caveat, or question.
Salman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: